Trevi Therapeutics announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at $4.00 per share. This offering is expected to generate total proceeds of $50 million before deducting underwriting discounts and commissions.
All shares in the offering are being sold by Trevi Therapeutics. The offering is anticipated to close on December 17, 2024, subject to customary closing conditions.
The financing includes participation from new and existing investors, including Adage Capital Partners LP, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital Management LP, and Vivo Capital. This capital raise is intended to support the continued development of Haduvio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.